Predictive importance of systemic inflammation response index in de novo brain metastatic small cell lung cancer patients

Yıl 2023, Cilt: 6 Sayı: 6, 1205 - 1209, 29.10.2023

Mustafa Büyükkör Necati Alkış

https://doi.org/10.32322/jhsm.1343077

Öz

Aims: The subtype of lung cancer, known as small cell lung cancer (SCLC), tends to have a highly fatal course, especially in advanced stages. In particular, the overall survival durations further decrease in cases of brain metastases in SCLC. There is increasing evidence for the role of systemic inflammation parameters in predicting cancer prognosis, and they appear likely to become potential target markers for clinical treatments in the future. We aimed to evaluate the systemic inflammation response index (SIRI), a novel inflammatory laboratory marker that could predict long-term survival and serve as a potential target marker for clinical treatment, in patients with de novo brain metastatic small cell lung carcinoma (DNBM SCLC)."
Methods: Clinicopathological features of adult patients diagnosed with DNBM SCLC were recorded from the patient registry of the hospital. Patients without medical records were not included in the study. Investigations were carried out to assess the prognostic effect of the SIRI parameter in predicting the 12-month overall survival (OS12) in DNBM SCLC patients, by determining a cut-off value and conducting appropriate statistical analyses, considering p-values (<0.05) as statistically significant.
Results: In this study 256 SCLC patients screened from the hospital database and detected 42 patients with de novo brain metastases (DNBM) were included in the study.The median age of patients was 61; 85.7% of the sample was male while 14.3% was female. When the SIRI marker was 1.79 or below, OS12 in patients was statistically significantly better predicted than in those with values above 1.79 (Cut off ≤ 1.79 AUC: 0.751, sensitivity: 66.7%, specificity: 66.7%; p=0.022). Also, SIRI ≤ 1.79 was found to be an independent variable predicting OS12 in DNBM SCLC patients.
Conclusion: Our study is important in terms of the short overall survival durations observed in DNBM SCLC patients and the identification of conventional laboratory parameters that can be used to predict longer survival durations in these patients.

Anahtar Kelimeler

small cell lung cancer, systemic inflammation, 12-month overall survival, brain metastasis

Kaynakça

• World Health Organization 2019. International agency for research on cancer. Available at: https://www.iarc.who.int/
• Remon J, Aldea M, Besse B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021;32(6);698-709.
• Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lungcancer. Lancet (London, England). 2021;398(10299);535-554.
• Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest. 2018;154(6);1284-1290.
• Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lungcancer. 2014;86(1);78-84.
• Manapov F, Käsmann L, Roengvoraphoj O, et al. Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes. Lung Cancer (Auckl). 2018;9:49-55.
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: A Cancer J Clin. 2021;71(1):7-33.
• Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long-term survival with metastatic cancer to the brain. Med Oncol (Northwood, London, England). 2000;17(4):279-286.
• Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment. Biochim Biophys Acta Mol Basis Dis. 2022;1868(12):166557.
• Priego N, Zhu L, Monteiro C, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24(7):1024-1035.
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
• Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631.
• Jiang S, Wang S, Wang Q, et al. Systemic inflammation response index (SIRI) independently predicts survival in advanced lung adenocarcinoma patients treated with first-generation EGFR-TKIs. Cancer Manag Res. 2021;13:1315-1322.
• Buyukkor M, Tay F, Ates O. Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib. J Oncol Pharm Pract. 2022;28(8):1906-1909.
• Yilmaz H, Yersal Ö. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. J Cancer Res Tther. 2022;18(3):691-696.
• Tay F, Buyukkor M, Duran AO. Prognostic importance of combined use of MELD scores and SII in hepatic visceral crisis in patients with solid tumours. Age. 2023;50(82):27-28.
• Li H, Wang G, Zhang H, et al. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations. Gen Immun. 2019;20(6):455-461.
• Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Prim. 2021;7(1):3.
• Klein-Weigel PF, Elitok S, Ruttloff A, et al. Superior vena cava syndrome. VASA. Zeitschrift fur Gefasskrankheiten. 2020;49(6):437-448.
• Rowell, N. P.,& Gleeson, F. V. Steroids, radiotherapy, chemotherapyand stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clinicaloncology (RoyalCollege of Radiologists (Great Britain)). 2002;14(5):338-351.
• Fiordoliva I, Meletani T, Baleani MG, et al. Managing hyponatremia in lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(11):711-719.
• Wang Z, Li J, Yuan Y, Li T, Zuo M, Liu Y. Prognostic significance of preoperative systemic inflammation response index in newly diagnosed glioblastoma patients underwent gross total resection: a propensity score matching analysis. World J Surg Oncol. 2022;20(1):137.
• Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic inflammation response index as a prognostic marker in cancer patients: a systematic review and meta-analysis of 38 cohorts. Dose-Response. 2021;19(4):15593258211064744.
• Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019;125(1):127-134.
• Stühler V, Herrmann L, Rausch S, Stenzl A, Bedke J. Role of the systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with first-line Ipilimumab plus Nivolumab. Cancers. 2022;14(12):2972.